RNA Virus Infections clinical trials at UCSF

1 research study open to eligible people

RNA virus infections are illnesses caused by viruses that use RNA as their genetic material. UCSF is studying a vaccine strategy to improve immune responses against these viruses in a clinical trial. Another trial is exploring treatments to better prepare our immune system for varied viral challenges.

Showing trials for

  • T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

    open to eligible people ages 40-64

    The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64. The CoTend-s3BXBB vaccine includes a component called "s3", which was designed to improve the body's response to the vaccine. CoTend-BXBB is the same vaccine without s3. The main questions the study aims to answer are: 1) Is the investigational vaccine safe? 2) Does "s3" lead to bigger, broader, and longer-lasting responses to the vaccine? 5 different doses of the vaccines will be studied. Participants will receive a single dose of either CoTend-s3BXBB, CoTend-BXBB, or placebo. Participants will be monitored for side effects. Saliva, nasal, and blood samples will be collected and immune responses to the vaccine will be measured.

    San Francisco, California and other locations

Our lead scientists for RNA Virus Infections research studies include .

Last updated: